Mapping the progression of atrophy in early and late onset Alzheimer’s disease

Manuscript Number: 

14-2292R1

Author(s): 
Federica Agosta, Elisa Canu, Massimo Filippi, Maria Luisa Gorno-Tempini, Raffaella Migliaccio, Bruce L. Miller, Katherine L. Possin, Gil D. Rabinovici, Howard J. Rosen

Disclosures

Federica Agosta

  • Lecture Fees:
    Biogen Idec and EXCEMED– Excellence in Medical Education

Elisa Canu

  • Nothing to Disclose

Massimo Filippi

  • Consulting Fees:
    Advisory Board for Teva Pharmaceutical Industries Ltd. Consultant for Bayer Schering Pharma, Biogen Idec, Merck Serono, and Teva Pharmaceutical Industries
    Lecture Fees:
    Bayer Schering Pharma, Biogen Idec, Merck Serono, and Teva Pharmaceutical Industries
    Grants
    • Agency: 
      Bayer Schering Pharma

Maria Luisa Gorno-Tempini

  • Nothing to Disclose

Raffaella Migliaccio

  • Nothing to Disclose

Bruce L. Miller

  • Consulting Fees:
    Bruce L. Miller, MD receives grant support from the NIH/NIA and the Centers for Medicare & Medicaid Services (CMS) as grants for the Memory and Aging Center. As an additional disclosure, Dr. Miller serves as Medical Director for the John Douglas French Foundation; Scientific Director for the Tau Consortium; Director/Medical Advisory Board of the Larry L. Hillblom Foundation; and Scientific Advisory Board Member for the National Institute for Health Research Cambridge Biomedical Research Centre and its subunit, the Biomedical Research Unit in Dementia (UK).

Katherine L. Possin

  • Nothing to Disclose

Gil D. Rabinovici

  • Consulting Fees:
    Consulting fees: Piramal
    Lecture Fees:
    Speaking honoraria: Medscape, GE Healthcare
    Grants
    • Agency: 
      Avid Radiopharmaceuticals
      Dates: 
      April 2012 - present

Howard J. Rosen

  • Nothing to Disclose